Anthony Doyle
Chief Financial Officer at BioCryst Pharmaceuticals
For full year 2024, total revenue was $450,700,000 with Orlodeo contributing $437,700,000 of that. For quarter four, '17 point '2 million dollars or 13.9% of the $124,200,000 total for Orlodeo came from ex U. S, while for full year it was $51,700,000 or 11.8% of the $437,700,000 total. Operating expenses not including non cash stock compensation for the quarter were approximately $115,000,000 Operating expenses not including non cash non stock based comp for full year 2024 came in at $388,000,000 an increase of just $8,000,000 versus 2023. With revenue increasing $119,000,000 year over year and this small increase in OpEx, this resulted in an operating profit not including stock based comp of $62,900,000 That's an increase of $111,000,000 versus the non GAAP operating loss of $48,100,000 from 2023, a remarkable achievement that sets us up for 2025 and beyond.